Finding the effects of Novel Organometallic Compound Phenanthroline in High Risk Acute Myeloid Leukemia

Abstract

Acute myeloid leukemia (AML) is one of the common forms of acute leukemia, is a malignant disorder that is identified due to the aberrant growth and differentiation of hematopoietic stem cells (HSCs), leading to the accumulation of immature myeloblasts (precursor cells) in peripheral blood and the bone marrow. Being a heterogeneous disorder. AML is consisting of various combinations of genetic aberrations, one of them is t(6;9) DEK/CAN that results in the formation of chimeric gene encoding leukemia associated fusion proteins (LAFP). DEK/CAN is associated with subtype high risk AML that has poor prognosis. Currently no therapy other than standard chemotherapy is available for DEK/CAN positive AML. So, there is a need for effective targeted therapy for DEK/CAN-positive AML. The purpose of this research studywas to find out the antiproliferative activity and candidate targets of novel organometallic compound in high risk AML by using MTT assay and in silico approaches respectively. As an AML model we used DEK/CAN positive FKH-1 cell line. Our novel organometallic compound strongly interfered with the proliferation potential of FKH-1 cell line and added additive antiproliferative effects with imatinib. In addition, in silico methodology was established to carry out computer-based modeling and know about the active sites of different genes which can be targeted by different compounds/analogues. Further studies are required to find some novel candidate targets for therapeutic intervention